Abstract: The present invention provides a nucleic acid comprises a 5? untranslated region, an NS3 protein coding region, an NS4A protein coding region, an NS4B protein coding region, an NS5A protein coding region, an NS5B protein coding region, and a 3? untranslated region of a hepatitis C virus genome, wherein the nucleic acid has nucleotide substitutions causing one or more amino acid substitutions selected from the group consisting of M(1205)K, F(1548)L, C(1615)W, T(1652)N, A(2196)T, A(2218)S, H(2223)Q, Q(2281)R, K(2520)N, and G(2374)S, as defined using the amino acid sequence shown in SEQ ID NO: 6 in the Sequence Listing as a reference sequence, in the NS3 protein coding region, the NS5A protein coding region, or the NS5B protein coding region.
Type:
Grant
Filed:
December 25, 2009
Date of Patent:
September 16, 2014
Assignees:
Toray Industries, Inc., Japan as Represented by Director-General of National Institute of Infectious Diseases, Tokyo Metropolitan Institute of Medical Science
Abstract: The purpose of the present invention is to develop a method for producing a large amount of an insoluble aggregate that is equivalent to an insoluble aggregate formed in the brain of a patient. A method of producing an insoluble aggregate of a neurodegenerative-disease-related protein according to the present invention comprises the steps of: (1) introducing an insoluble fraction originated from the brain of a neurodegenerative disease patient into a cultured cell in which the neurodegenerative-disease-related protein can be expressed in a constitutive manner; (2) culturing the cultured cell into which the insoluble fraction has been introduced; and (3) extracting separating an insoluble fraction from the cultured cell. Optionally, the method may additionally comprise a step of amplifying the insoluble aggregate of the neurodegenerative-disease-related protein in the cultured cell.
Type:
Application
Filed:
May 18, 2012
Publication date:
September 4, 2014
Applicant:
TOKYO METROPOLITAN INSTITUTE OF MEDICAL SCIENCE
Abstract: The present invention provides a method for diagnosing schizophrenia, and a schizophrenia diagnostic reagent or device for use in the method. The present invention further provides a therapeutic or ameliorating agent for schizophrenia, which is effective for the treatment or amelioration of schizophrenia. The therapeutic or ameliorating agent for schizophrenia contains a carbonyl scavenger or a carbonyl-modified protein formation inhibitor as an active ingredient. The method for diagnosing schizophrenia according to the present invention includes measuring at least one parameter in a subject, the parameter being selected from the group consisting of: (1) a genetic abnormality of glyoxalase I gene; (2) the expression level or activity of glyoxalase I in a biological sample; (3) the amount of a carbonyl compound or a carbonyl-modified protein that is a protein modified with the carbonyl compound; and (4) the amount of pyridoxal in a biological sample.
Type:
Grant
Filed:
July 31, 2008
Date of Patent:
August 19, 2014
Assignees:
Tokyo Metropolitan Institute of Medical Science, Renascience Co., Ltd.
Abstract: The present invention provides a means to ensure a further increase in the therapeutic effects provided by enzyme replacement therapy against lysosomal disease. The present invention is directed to a recombinant human saposin B protein containing phosphorylated carbohydrate chains, a lysosomal enzyme activator comprising such a recombinant protein, and a pharmaceutical composition for treatment of lysosomal disease, which comprises such a recombinant protein and a lysosomal enzyme, etc.
Type:
Application
Filed:
November 21, 2011
Publication date:
August 7, 2014
Applicant:
TOKYO METROPOLITAN INSTITUTE OF MEDICAL SCIENCE
Abstract: The system of the present invention includes (a) means for displaying image information including a target image and a cursor image for tracking the target image; (b) means used when the subject moves the cursor image; (c) means for detecting the state of tracking the target image by the cursor image; (d) means for detecting the muscle active state of the subject using the means (b); (e) means for analyzing the tracking state detected by the means (c) and the muscle active state detected by the means (d); and (f) means for evaluating the motor function of the subject by using results of analysis obtained by the means (e) as indexes.
Type:
Grant
Filed:
February 26, 2008
Date of Patent:
July 29, 2014
Assignees:
Tokyo Metropolitan Institute of Medical Science, Tokyo Metropolitan Government
Abstract: A fetal movement information processing device and method for accurately grasping and predicting the healthy development state of a fetus, namely, the well-being state of the fetus by adequately detecting and recording information on the fetal movement of a pregnant woman.
Type:
Grant
Filed:
August 3, 2007
Date of Patent:
July 1, 2014
Assignee:
Tokyo Metropolitan Institute of Medical Science
Abstract: A polynucleotide encoding the amino acid shown in SEQ ID NO:2 or SEQ ID NO: 5, or encoding an amino acid sequence having not less than 98% identity thereto; preferably a polynucleotide comprising replacement of the amino acid corresponding to glutamic acid at position 1202 of SEQ ID NO:2 (position 177 of SEQ ID NO:5) with glycine, replacement of the amino acid corresponding to glutamic acid at position 1056 (position 31 of SEQ ID NO:5) with valine, and replacement of the amino acid corresponding to alanine at position 2199 (position 1174 of SEQ ID NO:5) with threonine.
Type:
Application
Filed:
November 13, 2013
Publication date:
June 26, 2014
Applicants:
PHOENIXBIO CO., LTD., TOKYO METROPOLITAN INSTITUTE OF MEDICAL SCIENCE
Abstract: The present invention provides, as an enzyme which can be used for enzyme replacement therapy for Fabry disease, a protein having ?-galactosidase activity, which shows no allergic adverse side effect, shows a high stability in blood, and can be easily incorporated into a cell of an affected organ. The protein of the present invention is a protein which has acquired ?-galactosidase activity by changing the structure of the active site of wild-type human ?-N-acetylgalactosaminidase.
Type:
Application
Filed:
January 23, 2014
Publication date:
June 19, 2014
Applicants:
ALTIF LABORATORIES, TOKYO METROPOLITAN INSTITUTE OF MEDICAL SCIENCE
Abstract: The present invention relates to a replicon RNA comprising a nucleotide sequence at least containing the 5? untranslated region, the nucleotide sequence encoding NS3 protein, NS4A protein, NS4B protein, NS5A protein and NS5B protein, and the 3? untranslated region on the genomic RNA of hepatitis C virus of genotype 2a.
Type:
Grant
Filed:
January 3, 2013
Date of Patent:
June 17, 2014
Assignees:
Toray Industries, Inc., Tokyo Metropolitan Institute of Medical Science
Inventors:
Takaji Wakita, Takanobu Kato, Tomoko Date
Abstract: The present subject matter relates to a cardio pulmonary resuscitation (CPR) device (102) including a backboard (110) to support a subject, and a constriction element (112) to constrict the subject. The constriction element (112) is connected to a decompression element (118). The decompression element (118) is disposed to be placed along the circumference of a thoracic region of the subject and is adapted to adhere to the subject on deployment. Further, a sternum compression unit (120) is attached to the decompression element (118) such that the sternum compression unit (120) is disposed on a side of the decompression element (118). Further, the constriction element (112) is adapted to be constricted and to be slackened for delivering active sternum compression, active circumferential compression, active sternum decompression and active circumferential decompression.
Type:
Application
Filed:
May 14, 2012
Publication date:
June 5, 2014
Applicant:
ALL INDIA INSTITUTE OF MEDICAL SCIENCES
Abstract: Disclosed is a transformed cell (a cell model) which can form a cytoplasmic inclusion body derived from TAR DNA-binding protein of 43 kDa (TDP-43) that is found in the brain of a patient suffering from a neurodegenerative disease such as FTLD and ALS. The transformed cell is characterized by having, introduced therein, a promoter capable of functioning in a host cell and a mutant TDP-43 gene.
Type:
Grant
Filed:
March 6, 2009
Date of Patent:
May 6, 2014
Assignee:
Tokyo Metropolitan Institute of Medical Science
Abstract: Disclosed is a transformed cell (a cell model) which can form a cytoplasmic inclusion body derived from TAR DNA-binding protein of 43 kDa (TDP-43) that is found in the brain of a patient suffering from a neurodegenerative disease such as FTLD and ALS. The transformed cell is characterized by having, introduced therein, a promoter capable of functioning in a host cell and a mutant TDP-43 gene.
Type:
Application
Filed:
December 4, 2013
Publication date:
April 10, 2014
Applicant:
TOKYO METROPOLITIAN INSTITUTE OF MEDICAL SCIENCE
Abstract: The present invention provides, as an enzyme which can be used for enzyme replacement therapy for Fabry disease, a protein having ?-galactosidase activity, which shows no allergic adverse side effect, shows a high stability in blood, and can be easily incorporated into a cell of an affected organ. The protein of the present invention is a protein which has acquired ?-galactosidase activity by changing the structure of the active site of wild-type human ?-N-acetylgalactosaminidase.
Type:
Grant
Filed:
November 2, 2012
Date of Patent:
March 11, 2014
Assignees:
Tokyo Metropolitan Institute of Medical Science, Altif Laboratories
Abstract: The present invention provides a pharmaceutical composition comprising a protein having ?-galactosidase activity for treating Fabry disease, which causes no allergic side effect, which is highly stable in blood (plasma) and which can readily be taken up by a cell of an affected organ. The pharmaceutical composition for treating Fabry disease of the invention comprises, for example, a protein which acquires an ?-galactosidase activity through alteration of the structure of the active site of wild-type human ?-N-acetylgalactosaminidase.
Type:
Application
Filed:
September 13, 2013
Publication date:
February 13, 2014
Applicants:
ALTIF LABORATORIES INC., TOKYO METROPOLITAN INSTITUTE OF MEDICAL SCIENCE
Abstract: A polynucleotide encoding the amino acid shown in SEQ ID NO:2 or SEQ ID NO: 5, or encoding an amino acid sequence having not less than 98% identity thereto; preferably a polynucleotide comprising replacement of the amino acid corresponding to glutamic acid at position 1202 of SEQ ID NO:2 (position 177 of SEQ ID NO:5) with glycine, replacement of the amino acid corresponding to glutamic acid at position 1056 (position 31 of SEQ ID NO:5) with valine, and replacement of the amino acid corresponding to alanine at position 2199 (position 1174 of SEQ ID NO:5) with threonine.
Type:
Grant
Filed:
August 25, 2010
Date of Patent:
December 17, 2013
Assignees:
Tokyo Metropolitan Institute of Medical Science, Phoenixbio Co., Ltd.
Abstract: A simulating training device for assessment of cervical dilatation is provided. The device includes a supporting platform, a rotating plastic drum rigidly connected to a shaft and having a plurality of rubber-lined holes of varying diameters, a box which covers the rotating drum and has an opening, an indexing mechanism which has a spring-loaded lock and a slotted indexing wheel, a turn wheel which has an indication arrow, and a scale which identifies a diameter of each of the plurality of rubber-lined holes. Rotation of the turn wheel and the slotted indexing wheel causes one of the plurality of rubber-lined holes to be positioned in the center of the opening of the box one at a time. The turn wheel, the rotating drum and indexing mechanism are synchronized such that the indicating arrow of the turn wheel points to the diameter of the positioned hole on the scale.
Type:
Application
Filed:
May 2, 2012
Publication date:
November 7, 2013
Applicant:
KRISHNA INSTITUTE OF MEDICAL SCIENCES UNIVERSITY
Abstract: Provided are a highly-safe recombinant vaccinia virus that is effective in preventing the onset of symptoms due to infection by novel influenza viruses, and a vaccine for the novel influenza viruses containing the recombinant vaccinia virus. This recombinant vaccinia virus is capable of expressing the hemagglutinin protein genes of the novel influenza virus. This novel influenza vaccine contains the recombinant vaccinia virus.
Type:
Application
Filed:
October 13, 2011
Publication date:
October 31, 2013
Applicants:
TOKYO METROPOLITAN INSTITUTE OF MEDICAL SCIENCE, NATIONAL UNIVERSITY CORPORATION HOKKAIDO UNIVERSITY, THE CHEMO-SERO-THERAPEUTIC RESEARCH INSTITUTE
Abstract: The present invention provides a pharmaceutical composition comprising a protein having ?-galactosidase activity for treating Fabry disease, which causes no allergic side effect, which is highly stable in blood (plasma) and which can readily be taken up by a cell of an affected organ. The pharmaceutical composition for treating Fabry disease of the invention comprises, for example, a protein which acquires an ?-galactosidase activity through alteration of the structure of the active site of wild-type human ?-N-acetylgalactosaminidase.
Type:
Grant
Filed:
May 19, 2008
Date of Patent:
October 29, 2013
Assignees:
Tokyo Metropolitan Institute of Medical Science, ALTIF Laboratories Inc.
Abstract: The present invention relates to a replicon RNA comprising a nucleotide sequence at least containing the 5? untranslated region, the nucleotide sequence encoding NS3 protein, NS4A protein, NS4B protein, NS5A protein and NS5B protein, and the 3? untranslated region on the genomic RNA of hepatitis C virus of genotype 2a.
Type:
Application
Filed:
January 3, 2013
Publication date:
July 18, 2013
Applicants:
TOKYO METROPOLITAN INSTITUTE OF MEDICAL SCIENCE, TORAY INDUSTRIES, INC.
Inventors:
Toray Industries, Inc., Tokyo Metropolitan Institute Of Medical Science, Ralf Bartenschlager